Inflammasomes contributing to inflammation in arthritis. Issue 1 (16th January 2020)

• Record Type: Journal Article
• Authors: Spel, Lotte; Martinon, Fabio
• Is Part Of: Immunological reviews. Volume 294:Issue 1(2020)
• Page Start: 48
• Page End: 62
• Publication Date: 2020-01-16
• Subjects: arthritis -- CARD8 -- gout -- inflammasome -- innate immunity -- NLRP3; Immunology -- Periodicals; Transplantation of organs, tissues, etc -- Periodicals; 616.079
• DOI: 10.1111/imr.12839
• Languages: English
• ISSNs: 0105-2896

Abstract

Abstract: Inflammasomes are intracellular multiprotein signaling platforms that initiate inflammatory responses in response to pathogens and cellular damage. Active inflammasomes induce the enzymatic activity of caspase‐1, resulting in the induction of inflammatory cell death, pyroptosis, and the maturation and secretion of inflammatory cytokines IL‐1β and IL‐18. Inflammasomes are activated in many inflammatory diseases, including autoinflammatory disorders and arthritis, and inflammasome‐specific therapies are under development for the treatment of inflammatory conditions. In this review, we outline the different inflammasome platforms and recent findings contributing to our knowledge about inflammasome biology in health and disease. In particular, we discuss the role of the inflammasome in the pathogenesis of arthritic diseases, including rheumatoid arthritis, gout, ankylosing spondylitis, and juvenile idiopathic arthritis, and the potential of newly developed therapies that specifically target the inflammasome or its products for the treatment of inflammatory diseases.